Does the media refer more to CRVS or ACAD?

In the previous week, ACADIA Pharmaceuticals had 24 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 9 mentions for Corvus Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat Corvus Pharmaceuticals' score of -0.17 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, CELC or CRVS?

Celcuity is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$3.90 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is CELC or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -244.61% -50.22% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media refer more to CELC or CRVS?

In the previous week, Celcuity had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 10 mentions for Celcuity and 9 mentions for Corvus Pharmaceuticals. Celcuity's average media sentiment score of 0.25 beat Corvus Pharmaceuticals' score of -0.17 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corvus Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, CRVS or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is CRVS or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% Parabilis Medicines N/A N/A N/A

Is TNGX or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -41.54% -33.44% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media refer more to TNGX or CRVS?

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Corvus Pharmaceuticals and 5 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.50 beat Corvus Pharmaceuticals' score of -0.17 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, VKTX or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is VKTX or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -94.56% -82.75% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media prefer VKTX or CRVS?

In the previous week, Viking Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 10 mentions for Viking Therapeutics and 9 mentions for Corvus Pharmaceuticals. Viking Therapeutics' average media sentiment score of 1.23 beat Corvus Pharmaceuticals' score of -0.17 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Corvus Pharmaceuticals (CRVS) Competitors

$13.50 -0.42 (-3.02%)

As of 12:24 PM Eastern

Compare

CRVS vs. ACAD, CELC, PBLS, TNGX, and VKTX

Should you buy Corvus Pharmaceuticals stock or one of its competitors? MarketBeat compares Corvus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corvus Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Celcuity (CELC), Parabilis Medicines (PBLS), Tango Therapeutics (TNGX), and Viking Therapeutics (VKTX). These companies are all part of the "biotechnology" industry.

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

ACADIA Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
ACADIA Pharmaceuticals	$1.07B	4.72	$391M	$2.22	13.21

In the previous week, ACADIA Pharmaceuticals had 24 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 9 mentions for Corvus Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat Corvus Pharmaceuticals' score of -0.17 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals currently has a consensus price target of $33.33, indicating a potential upside of 146.66%. ACADIA Pharmaceuticals has a consensus price target of $33.44, indicating a potential upside of 14.04%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Corvus Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Corvus Pharmaceuticals' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Corvus Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Summary

ACADIA Pharmaceuticals beats Corvus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Celcuity?

Celcuity (NASDAQ:CELC) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Celcuity currently has a consensus price target of $155.18, indicating a potential upside of 69.94%. Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 146.66%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Corvus Pharmaceuticals' return on equity of -36.15% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-244.61%	-50.22%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Celcuity has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

In the previous week, Celcuity had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 10 mentions for Celcuity and 9 mentions for Corvus Pharmaceuticals. Celcuity's average media sentiment score of 0.25 beat Corvus Pharmaceuticals' score of -0.17 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 13.3% of Celcuity shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Celcuity is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Summary

Corvus Pharmaceuticals beats Celcuity on 10 of the 14 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Parabilis Medicines?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, suggesting a potential upside of 146.66%. Parabilis Medicines has a consensus target price of $41.67, suggesting a potential upside of 16.03%. Given Corvus Pharmaceuticals' higher probable upside, equities research analysts clearly believe Corvus Pharmaceuticals is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Parabilis Medicines' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Parabilis Medicines	N/A	N/A	N/A

In the previous week, Corvus Pharmaceuticals had 9 more articles in the media than Parabilis Medicines. MarketBeat recorded 9 mentions for Corvus Pharmaceuticals and 0 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.00 beat Corvus Pharmaceuticals' score of -0.17 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Overall Sentiment
Corvus Pharmaceuticals	Neutral
Parabilis Medicines	Neutral

Summary

Corvus Pharmaceuticals beats Parabilis Medicines on 5 of the 9 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Tango Therapeutics presently has a consensus target price of $42.15, indicating a potential upside of 55.23%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 146.66%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Corvus Pharmaceuticals' return on equity of -36.15% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Corvus Pharmaceuticals and 5 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.50 beat Corvus Pharmaceuticals' score of -0.17 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Corvus Pharmaceuticals has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	62.97	-$101.59M	-$0.83	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Tango Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Summary

Corvus Pharmaceuticals beats Tango Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

In the previous week, Viking Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 10 mentions for Viking Therapeutics and 9 mentions for Corvus Pharmaceuticals. Viking Therapeutics' average media sentiment score of 1.23 beat Corvus Pharmaceuticals' score of -0.17 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals' return on equity of -36.15% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Viking Therapeutics currently has a consensus target price of $97.88, indicating a potential upside of 185.70%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 146.66%. Given Viking Therapeutics' higher probable upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Corvus Pharmaceuticals beats Viking Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Corvus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVS vs. The Competition

Export

Metric	Corvus Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.14B	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-22.18	9.06	269.91	24.87
Price / Sales	N/A	1,278.42	654.69	108.21
Price / Cash	109.82	44.95	28.89	37.44
Price / Book	18.51	17.97	11.40	6.45
Net Income	-$15.28M	-$13.25M	$3.45B	$347.50M
7 Day Performance	1.08%	5.58%	3.66%	3.77%
1 Month Performance	-13.76%	-1.60%	-0.49%	-0.40%
1 Year Performance	213.55%	61.32%	77.51%	23.55%

Corvus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVS Corvus Pharmaceuticals	2.9005 of 5 stars	$13.50 -3.0%	$33.33 +146.9%	+223.0%	$1.13B	N/A	N/A	30	News Coverage Positive News Earnings Report
ACAD ACADIA Pharmaceuticals	4.2849 of 5 stars	$27.15 +6.0%	$32.31 +19.0%	+18.7%	$4.39B	$1.07B	12.34	510	Earnings Report Analyst Upgrade Insider Trade Analyst Revision
CELC Celcuity	2.9883 of 5 stars	$92.49 +5.4%	$155.18 +67.8%	+102.2%	$4.28B	N/A	N/A	40	Upcoming Earnings
PBLS Parabilis Medicines	2.3222 of 5 stars	$35.90 +5.7%	$41.67 +16.1%	N/A	$4.24B	N/A	N/A	N/A	Positive News
TNGX Tango Therapeutics	2.2673 of 5 stars	$29.36 +7.9%	$42.15 +43.6%	+309.5%	$3.94B	$62.38M	N/A	90	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. ACAD, CELC, PBLS, TNGX, and VKTX

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

How does Corvus Pharmaceuticals compare to Celcuity?

Summary

How does Corvus Pharmaceuticals compare to Parabilis Medicines?

Summary

How does Corvus Pharmaceuticals compare to Tango Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. ACAD, CELC, PBLS, TNGX, and VKTX

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

Which has preferable earnings & valuation, CRVS or ACAD?

Does the media refer more to CRVS or ACAD?

Do analysts recommend CRVS or ACAD?

Do institutionals and insiders have more ownership in CRVS or ACAD?

Is CRVS or ACAD more profitable?

Which has more risk and volatility, CRVS or ACAD?

Summary

How does Corvus Pharmaceuticals compare to Celcuity?

Do analysts rate CELC or CRVS?

Is CELC or CRVS more profitable?

Which has more volatility & risk, CELC or CRVS?

Does the media refer more to CELC or CRVS?

Do insiders and institutionals believe in CELC or CRVS?

Which has preferable valuation and earnings, CELC or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Parabilis Medicines?

Do analysts rate CRVS or PBLS?

Which has better valuation and earnings, CRVS or PBLS?

Do institutionals and insiders hold more shares of CRVS or PBLS?

Is CRVS or PBLS more profitable?

Does the media prefer CRVS or PBLS?

Summary

How does Corvus Pharmaceuticals compare to Tango Therapeutics?

Do analysts prefer TNGX or CRVS?

Is TNGX or CRVS more profitable?

Does the media refer more to TNGX or CRVS?

Do institutionals & insiders believe in TNGX or CRVS?

Which has better earnings & valuation, TNGX or CRVS?

Which has more risk & volatility, TNGX or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Viking Therapeutics?

Which has better valuation and earnings, VKTX or CRVS?

Does the media prefer VKTX or CRVS?

Is VKTX or CRVS more profitable?

Do insiders and institutionals have more ownership in VKTX or CRVS?

Which has more risk and volatility, VKTX or CRVS?

Do analysts prefer VKTX or CRVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools